John E. Kraus

Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study

Thomas Voit, Haluk Topaloğlu, Volker Straub et al. · The Lancet Neurology · 2014 · 295 citations

Medicine, Pharmacology, Pharmacotherapy +5

A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis

Johnny Peppers, Amy S. Paller, Tomoko Maeda‐Chubachi et al. · Journal of the American Academy of Dermatology · 2018 · 164 citations

Medicine, Dermatology, Pharmacotherapy +7

A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy

Nathalie Goemans, Eugenio Mercuri, Hirofumi Komaki et al. · Neuromuscular Disorders · 2017 · 128 citations · Full text

Medicine, Molecular Medicine, Neuromuscular Disorders +7

Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis

K. Thomas Robbins, Robert Bissonnette, Tomoko Maeda‐Chubachi et al. · Journal of the American Academy of Dermatology · 2018 · 94 citations

Medicine, Dermatology, Pharmacotherapy +5

Differences in Medication Adherence and Healthcare Resource Utilization Patterns

David V. Sheehan, Michael Eaddy, Stan Krulewicz et al. · CNS Drugs · 2008 · 90 citations

Pharmacy, Clinical Pharmacy, Pharmacotherapy +14